279 related articles for article (PubMed ID: 18172433)
1. Novel drugs and therapeutic targets for severe mood disorders.
Mathew SJ; Manji HK; Charney DS
Neuropsychopharmacology; 2008 Aug; 33(9):2080-92. PubMed ID: 18172433
[TBL] [Abstract][Full Text] [Related]
2. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder.
Zarate CA; Singh J; Manji HK
Biol Psychiatry; 2006 Jun; 59(11):1006-20. PubMed ID: 16487491
[TBL] [Abstract][Full Text] [Related]
3. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
Manji HK; Bebchuk JM; Moore GJ; Glitz D; Hasanat KA; Chen G
J Clin Psychiatry; 1999; 60 Suppl 2():27-39; discussion 40-1, 113-6. PubMed ID: 10073385
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
Gould TD; Manji HK
Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
[TBL] [Abstract][Full Text] [Related]
5. Intracellular signaling pathways pave roads to recovery for mood disorders.
Tanis KQ; Duman RS
Ann Med; 2007; 39(7):531-44. PubMed ID: 17852035
[TBL] [Abstract][Full Text] [Related]
6. Critical role of brain-derived neurotrophic factor in mood disorders.
Hashimoto K; Shimizu E; Iyo M
Brain Res Brain Res Rev; 2004 May; 45(2):104-14. PubMed ID: 15145621
[TBL] [Abstract][Full Text] [Related]
7. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.
Machado-Vieira R; Salvadore G; Ibrahim LA; Diaz-Granados N; Zarate CA
Curr Pharm Des; 2009; 15(14):1595-611. PubMed ID: 19442176
[TBL] [Abstract][Full Text] [Related]
8. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers.
Manji HK; Chen G
Mol Psychiatry; 2002; 7 Suppl 1():S46-56. PubMed ID: 11986995
[TBL] [Abstract][Full Text] [Related]
9. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder.
Einat H; Manji HK
Biol Psychiatry; 2006 Jun; 59(12):1160-71. PubMed ID: 16457783
[TBL] [Abstract][Full Text] [Related]
10. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers.
Gould TD; Quiroz JA; Singh J; Zarate CA; Manji HK
Mol Psychiatry; 2004 Aug; 9(8):734-55. PubMed ID: 15136794
[TBL] [Abstract][Full Text] [Related]
11. Glutamate modulators as novel interventions for mood disorders.
Mathew SJ; Keegan K; Smith L
Braz J Psychiatry; 2005 Sep; 27(3):243-8. PubMed ID: 16224615
[TBL] [Abstract][Full Text] [Related]
12. Mood-stabilizing drugs: are their neuroprotective aspects clinically relevant?
Lagace DC; Eisch AJ
Psychiatr Clin North Am; 2005 Jun; 28(2):399-414. PubMed ID: 15826739
[TBL] [Abstract][Full Text] [Related]
13. Search for a common mechanism of mood stabilizers.
Harwood AJ; Agam G
Biochem Pharmacol; 2003 Jul; 66(2):179-89. PubMed ID: 12826261
[TBL] [Abstract][Full Text] [Related]
14. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials.
Chuang DM
Ann N Y Acad Sci; 2005 Aug; 1053():195-204. PubMed ID: 16179524
[TBL] [Abstract][Full Text] [Related]
15. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.
Krystal JH; Sanacora G; Blumberg H; Anand A; Charney DS; Marek G; Epperson CN; Goddard A; Mason GF
Mol Psychiatry; 2002; 7 Suppl 1():S71-80. PubMed ID: 11986998
[TBL] [Abstract][Full Text] [Related]
16. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.
Manji HK; Quiroz JA; Sporn J; Payne JL; Denicoff K; A Gray N; Zarate CA; Charney DS
Biol Psychiatry; 2003 Apr; 53(8):707-42. PubMed ID: 12706957
[TBL] [Abstract][Full Text] [Related]
17. The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers.
Chen G; Manji HK
Curr Opin Psychiatry; 2006 May; 19(3):313-23. PubMed ID: 16612219
[TBL] [Abstract][Full Text] [Related]
18. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
Gould TD; Picchini AM; Einat H; Manji HK
Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
[TBL] [Abstract][Full Text] [Related]
19. Lithium neuroprotection: molecular mechanisms and clinical implications.
Rowe MK; Chuang DM
Expert Rev Mol Med; 2004 Oct; 6(21):1-18. PubMed ID: 15488156
[TBL] [Abstract][Full Text] [Related]
20. Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder.
Soeiro-de-Souza MG; Dias VV; Figueira ML; Forlenza OV; Gattaz WF; Zarate CA; Machado-Vieira R
Acta Psychiatr Scand; 2012 Nov; 126(5):332-41. PubMed ID: 22676371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
